Ana A. Tula-Sanchez, Ph.D.
Affiliations: | 2013 | Pharmacology & Toxicology | University of Arizona, Tucson, AZ |
Area:
Pharmacology, OncologyGoogle:
"Ana Tula-Sanchez"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Catharine L. Smith | grad student | 2013 | University of Arizona | |
| (Elucidation of the Mechanisms of Resistance and Sensitivity to Histone Deacetylase Inhibitor, PXD101, in Diffuse Large B-cell Lymphoma (DLBCL).) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Havas AP, Tula-Sanchez AA, Steenhoek HM, et al. (2023) Defining cellular responses to HDAC-selective inhibitors reveals that efficient targeting of HDAC3 is required to elicit cytotoxicity and overcome naïve resistance to pan-HDACi in diffuse large B cell lymphoma. Translational Oncology. 39: 101779 |
| Havas AP, Rodrigues KB, Bhakta A, et al. (2016) Belinostat and Vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive diffuse large B cell lymphoma. Cancer Biology & Therapy. 0 |
| Peters TL, Li L, Tula-Sanchez AA, et al. (2016) Control of translational activation by PIM kinase in activated B-cell diffuse large B-cell lymphoma confers sensitivity to inhibition by PIM447. Oncotarget |
| Peters TL, Tula-Sanchez AA, Li L, et al. (2014) Activated B-Cell DLBCL with Downstream Activation of Survival Signaling Requires PIM Kinase Activity to Maintain Oncoprotein Translation Blood. 124: 4496-4496 |
| Tula-Sanchez AA, Havas AP, Alonge PJ, et al. (2013) A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors. Cancer Biology & Therapy. 14: 949-61 |
| Tula-Sanchez AA, Havas A, Alonge P, et al. (2012) Mechanisms of Sensitivity and Resistance to Histone Deacetylase Inhibitors in Diffuse Large B-Cell Lymphoma Blood. 120: 1359-1359 |
| Tula-Sanchez AA, Klein ME, Smith CL, et al. (2011) Abstract 597: The cellular and genomic response to histone deacetylase inhibitors in diffuse large b-cell lymphoma Cancer Research. 71: 597-597 |